Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease
Author(s): Federica Piani , Lorenzo Annesi , Claudio Borghi Added: 6 months ago

Heart Failure

Prevention & Chronic Conditions
FLOW: Kidney, Cardiovascular, Mortality, Metabolic and Safety Results
Author(s): Richard Pratley Added: 1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
What Matters to Patients: Metabolic Health Beyond Weight Loss
Author(s): Lee Kaplan , Fatima Cody Stanford , Filip Knop , et al Added: 2 years ago
Radcliffe Medical Education bring together a distinguished panel of globally renowned experts who provide guidance on navigating the ever-changing landscape of obesity and metabolic health management. Under the chairmanship of Prof Jason Halford(University of Leeds, UK), the panel includingDr Lee Kaplan(Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, US),Dr… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 1 month ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Cardiac Troponins in Kidney Disease
Author(s): Daniel Murphy , Debasish Banerjee Added: 3 months ago

Heart Failure
Multimodality Imaging in Cardiac Amyloidosis with Dr Vasvi Singh
Author(s): Vasvi Singh Added: 3 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights… View more

Heart Failure

Imaging & Diagnostics
Treatment Landscape for Cardiac Amyloidosis with Dr Sarah Cuddy
Author(s): Added: 3 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly… View more

Heart Failure
ESC 25 Hot Line Discussion: DIGIT-HF: Cardiac Glycosides in HFrEF
Author(s): Harriette Van Spall , Udo Bavendiek Added: 3 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study… View more

Heart Failure

Prevention & Chronic Conditions
ACC 25: Cardiac Biomarker Analysis from the EARLY TAVR Trial
Author(s): Brian Lindman Added: 8 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more

Vascular Disease and Surgery